440 related articles for article (PubMed ID: 23449634)
1. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
Rosenstock J; Marx N; Kahn SE; Zinman B; Kastelein JJ; Lachin JM; Bluhmki E; Patel S; Johansen OE; Woerle HJ
Diab Vasc Dis Res; 2013 Jul; 10(4):289-301. PubMed ID: 23449634
[TBL] [Abstract][Full Text] [Related]
2. [Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA® trial].
Gallwitz B; Thiemann S; Wörle HJ; Marx N
Dtsch Med Wochenschr; 2015 May; 140(11):831-4. PubMed ID: 26080724
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.
Scheen AJ
Diabetes Metab; 2018 Nov; 44(5):386-392. PubMed ID: 30126735
[TBL] [Abstract][Full Text] [Related]
4. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
Santamarina M; Carlson CJ
BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
[TBL] [Abstract][Full Text] [Related]
5. Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?
John M; Kalra S; Nair T
Indian Heart J; 2020; 72(4):312-315. PubMed ID: 32861392
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
Biessels GJ; Janssen J; van den Berg E; Zinman B; Espeland MA; Mattheus M; Johansen OE;
BMC Neurol; 2018 Jan; 18(1):7. PubMed ID: 29334906
[TBL] [Abstract][Full Text] [Related]
7. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
9. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
Marx N; Kolkailah AA; Rosenstock J; Johansen OE; Cooper ME; Alexander JH; Toto RD; Wanner C; Espeland MA; Mattheus M; Schnaidt S; Perkovic V; Gollop ND; McGuire DK
JAMA Cardiol; 2024 Feb; 9(2):134-143. PubMed ID: 38170502
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.
Bain S; Druyts E; Balijepalli C; Baxter CA; Currie CJ; Das R; Donnelly R; Khunti K; Langerman H; Leigh P; Siliman G; Thorlund K; Toor K; Vora J; Mills EJ
Diabetes Obes Metab; 2017 Mar; 19(3):329-335. PubMed ID: 27862902
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
Home P
Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
[TBL] [Abstract][Full Text] [Related]
12. Do sulphonylureas still have a place in clinical practice?
Khunti K; Chatterjee S; Gerstein HC; Zoungas S; Davies MJ
Lancet Diabetes Endocrinol; 2018 Oct; 6(10):821-832. PubMed ID: 29501322
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA.
Ghosh S; Mukhopadhyay P; Pandey P; Chatterjee P; Pandit K
Diab Vasc Dis Res; 2020; 17(6):1479164120973653. PubMed ID: 33213193
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
Patil HR; Al Badarin FJ; Al Shami HA; Bhatti SK; Lavie CJ; Bell DS; O'Keefe JH
Am J Cardiol; 2012 Sep; 110(6):826-33. PubMed ID: 22703861
[TBL] [Abstract][Full Text] [Related]
15. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Kumar A
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
[TBL] [Abstract][Full Text] [Related]
16. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.
Davidson MH
Postgrad Med; 2014 May; 126(3):56-65. PubMed ID: 24918792
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care.
Patorno E; Gopalakrishnan C; Brodovicz KG; Meyers A; Bartels DB; Liu J; Kulldorff M; Schneeweiss S
Diabetes Obes Metab; 2019 Aug; 21(8):1824-1836. PubMed ID: 30941884
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
Espeland MA; Pratley RE; Rosenstock J; Kadowaki T; Seino Y; Zinman B; Marx N; McGuire DK; Andersen KR; Mattheus M; Keller A; Weber M; Johansen OE
Diabetes Obes Metab; 2021 Feb; 23(2):569-580. PubMed ID: 33185002
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.
Yandrapalli S; Jolly G; Horblitt A; Pemmasani G; Sanaani A; Aronow WS; Frishman WH
Cardiol Rev; 2020; 28(4):177-189. PubMed ID: 32282393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]